Multiple Sclerosis (MS)
Select from the various topics below and click on the link to get an inside view of how our P&T committee responded to the issue.
PML Cases with Monotherapy Tysabri Worldwide Since Reintroduction to the Market
Comparative Efficacy of Interferons and Copaxone vs. Higher Side Effects for Tysabri
Novartis and Bayer Agreement on Extavia as a Market Entry Strategy
Copaxone, Betaseron, Avonex and Rebif Clinical Differentiation
Earlier Use of Interferons and Copaxone in Disease Progression
Importance of New Indications Highlighting Copaxone's New Indication for First Clinical Episode
Impact of Injection Site Reactions with Rebif as Compared to Avonex on Compliance and Preference
Financial and Contracting Comparison of Rebif and Betaseron
Efficacy and Side Effect Comparison of Rebif, Betaseron and Avonex
Effect of Neutralizing Antibodies on Response Rate for Interferons and Copaxone
Neurologist Preference Among Avonex, Betaseron adn Rebif: Higher Potency vs. More Frequent Dosing
Neurologist Therapy Protocol for First-line Biologics
Cost Comparison Across Avonex, Rebif, Betaseron and Copaxone
Total Cost and Utilization Associated with Members with MS
Formulary Essentials Among Copaxone, Avonex, Rebif and Betaseron
Contracting Changes Moving Non-preferred Agents to Preferred and Moving Share Consideration
PA Requirements for Avonex and Betaseron
Betaseron and Extavia Comparison
Extavia Price Threshold to Obtain Preferred Status
Patient Willingness to Switch for Lower OOP Costs
* PTP video clips play in windows media
player. To download
click here,
Mac users
click here.